Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | PDE5A | O76074 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16131556 | 0.88 | PDE5A (0.43) | DYRK1APDE5AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL18328990 | 0.83 | DYRK1A (0.44) | DYRK1APDE5AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL18328950 | 0.82 | ALDH1A1 (0.40) | PDE5AKDM4EHSD17B10ALDH1A1MAPK1 | |
| SCHEMBL16131541 | 0.80 | KDM4E (0.48) | DYRK1APDE5AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL13418951 | 0.75 | MYLK (0.45) | DYRK1AKDM4EHSD17B10ALDH1A1MAPK1 | |
| SCHEMBL18328997 | 0.74 | TP53 (0.34) | KDM4EALDH1A1HTTCNR2 | |
| SCHEMBL18328988 | 0.71 | MAOA (0.36) | KDM4EALDH1A1MAPK1HTTMAOA | |
| SCHEMBL15848953 | 0.70 | G6PD (0.45) | KDM4EHSD17B10ALDH1A1MAPK1 | |
| SCHEMBL28948755 | 0.69 | DYRK1A (0.58) | DYRK1APDE5AKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL18329000 | 0.69 | SIGMAR1 (0.34) | PDE5AKDM4EALDH1A1MAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | PANACELA LABS, INC. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368872-A1 | COMPOUNDS AND METHODS FOR TREATING CANCERS | KLK3, AR, BRDT | DYRK1A 2114/4885PDE5A 1031/4885KDM4E 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.